Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance.
about
Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol.High-level expression of biologically active human alpha 1-antitrypsin in the milk of transgenic micePseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.A review of augmentation therapy for alpha-1 antitrypsin deficiency.Transgenic approaches for modifying the mammary gland to produce therapeutic proteinsAerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method.Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep.Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency.Mouse respiratory tract dendritic cell subsets and the immunological fate of inhaled antigens.Understanding Lung Deposition of Alpha-1 Antitrypsin in Acute Experimental Mouse Lung Injury Model Using Fluorescence MicroscopyAlpha-1 antitrypsin (AAT) deficiency - what are the treatment options?Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosisBioavailability of therapeutic proteins by inhalation--worker safety aspects.Current status of gene therapy for α-1 antitrypsin deficiency.Pulmonary cell biology.Increased prevalence of the alpha-1-antitrypsin (A1AT) deficiency-related S gene in patients infected with human immunodeficiency virus type 1.Genetics and lung disease.Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor.Expression of human alpha 1-antitrypsin using a recombinant adenovirus vector.Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment.Recent advances in pulmonary drug delivery using large, porous inhaled particles.Delivery of Alpha-1 Antitrypsin to Airways.
P2860
Q33602209-2B64C808-AF97-43B8-97A2-6A9481442BE6Q33672151-58ED5444-91FD-4268-BD3F-76575A156529Q33901457-75192E99-3C6E-4C1E-B6D6-672E2D262501Q34180810-6A1B79F2-A12D-4C7F-BEC5-45F32FCB2EB9Q34268108-ECEC62F0-9BCF-4D87-A773-A8CA948CC41FQ35032214-C6067A62-21D4-48D8-AEBE-417BC9E3A714Q35780387-9C8EF1FF-77C1-4DC7-BEB7-212EEAAC958CQ35815514-F613215A-23C8-44A4-8EAE-ED268BAE758FQ35816451-33E81020-8723-4AFE-BAB2-2AAA3442324FQ36721954-BA9F0510-F96A-4E5F-AE4F-53D70AE56547Q37516657-17FABB62-F626-492E-BD3A-8CA7CBE193ABQ37614554-16F60D6A-F604-4833-A58A-C99B8020219EQ37774788-EEA81617-863D-447F-A0A5-205E19B75304Q37819431-9CC7BB15-997A-43B0-B1A5-C30B6C4886FBQ38222723-8FEFA218-C8C9-4C77-AA1B-7C42E5331DFBQ38264336-EC2A940E-1EB1-4EB9-9CF6-273CEEBD57CEQ41752319-78CF9353-57EE-45BE-95DD-D2D2A0C3BA21Q42262698-BF1D062E-80D5-46EE-B55D-D119438EAA97Q43164630-6475BD1C-9CF4-43EE-B0B1-6F51B5CE1BDBQ44223779-940A720F-5640-42C5-AD00-F27269420A72Q44357326-D71A22D8-1FE9-4200-8BA3-4F6B75EF900BQ46303528-CC65315B-28FA-4BE4-BAA4-D91EF6CB3850Q47748401-07FA1FDE-0BA7-4D73-AA44-4D50E048CE4FQ48093032-DDA09CA4-56DD-42E7-B0AC-77A000A4CBCD
P2860
Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Fate of aerosolized recombinan ...... ins of therapeutic importance.
@ast
Fate of aerosolized recombinan ...... ins of therapeutic importance.
@en
type
label
Fate of aerosolized recombinan ...... ins of therapeutic importance.
@ast
Fate of aerosolized recombinan ...... ins of therapeutic importance.
@en
prefLabel
Fate of aerosolized recombinan ...... ins of therapeutic importance.
@ast
Fate of aerosolized recombinan ...... ins of therapeutic importance.
@en
P2093
P2860
P356
P1476
Fate of aerosolized recombinan ...... ins of therapeutic importance.
@en
P2093
Casolaro MA
Crystal RG
Hubbard RC
Matthay MA
Mitchell M
Sellers SE
P2860
P304
P356
10.1073/PNAS.86.2.680
P407
P577
1989-01-01T00:00:00Z